Huss, Ryan S.

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 296

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 230

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 171

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and Outcomes

Cited by 9